Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Clin Pharmacokinet. 2018 May;57(5):577–589. doi: 10.1007/s40262-017-0576-7

Figure 2.

Figure 2

AAG ontogeny with respect to (A) PNA and (B) PMA in subjects diagnosed or suspected of infection. Median (i.e. geometric mean) AAG concentrations (solid lines) and associated 95% CI (dashed lines) as estimated using a sigmoid Emax model are depicted. Subjects from the each clinical trial (Staph Trio, □; PTN POPS ●;CLIN01 Δ) are denoted separately.